Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Takeda Pharmaceutical Co ( (JP:4502) ) is now available.
Takeda has approved the next phase of its corporate transformation aimed at boosting competitiveness and supporting long-term growth as it prepares for a wave of new product launches. The program is built around a streamlined organizational structure and seeks to better align leadership and operating teams with patients and customers.
The company plans to generate more than JPY 200 billion in annualized gross savings by FY2028 through simplifying corporate functions, leveraging advanced technologies and improving launch execution, while largely funding investments in late-stage assets such as oveporexton, rusfertide and zasocitinib. Takeda expects to book about JPY 150 billion in restructuring charges in FY2026, with smaller costs in subsequent years, but does not foresee a material impact on its FY2025 earnings outlook.
The most recent analyst rating on (JP:4502) stock is a Buy with a Yen6304.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Co., headquartered in Japan and listed in Tokyo and New York, is a values-driven, R&D-focused biopharmaceutical group. It develops and markets life-transforming treatments across gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines, serving patients in about 80 countries and regions worldwide.
Average Trading Volume: 5,094,805
Technical Sentiment Signal: Buy
Current Market Cap: Yen8840.6B
For a thorough assessment of 4502 stock, go to TipRanks’ Stock Analysis page.